ロード中...
Expanded use of rituximab in the management of non-Hodgkin lymphoma
Rituximab is a chimeric monoclonal antibody targeting the B cell antigen CD20. Since its first approval for clinical use in 1997, rituximab has become an inherent part of the treatment of CD20-positive lymphoma. In previously untreated non-Hodgkin lymphoma (NHL) conventional chemotherapy supplemente...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2009
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2886316/ https://ncbi.nlm.nih.gov/pubmed/20616906 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|